Kyowa Hakko Kogyo, Mitsubishi Pharma Obtain Additional Approval for Recombinant Alteplase Agents.Tokyo, Japan, Oct 17, 2005 - (JCNN JCNN Japan Corporate News Network ) - Kyowa Hakko Kogyo and Mitsubishi Pharma have obtained approval of additional indication for their recombinant alteplase agents, ACTIVACIN for Injection by Kyowa Hakko Kogyo and GRTPA inj. by Mitsubishi Pharma, from the Ministry of Health, Labor and Welfare, as of October 11. The respective agents are now available for the treatment of improving dysfunction caused by acute ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic cerebrovascular disease (within the first three hours of onset). The two agents, which were launched in Japan in May 1991, are based on a recombinant tissue plasminogen activator tissue plasminogen activator n. Abbr. TPA 1. An enzyme that catalyzes the conversion of plasminogen to plasmin, used to dissolve blood clots rapidly and selectively, especially in the treatment of heart attacks. 2. developed by US firm Genentech. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion